Mezagitamab for chronic ITP that hasn't responded to standard treatments
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a new medicine called mezagitamab for adults with chronic ITP (low platelets for at least a year) who have not responded well to standard treatments. It aims to see if mezagitamab can safely raise platelet counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had ITP for at least 12 months.
- You have tried at least one first-line treatment (like steroids) and one second-line treatment (like TPO-RA, rituximab, or mycophenolate) and they either did not work well or caused side effects.
- Your platelet count is under 30,000/µL (based on recent blood tests).
- You have not had a blood clot or spleen removal in the past year.
- You do not have active hepatitis B, C, or HIV, and you haven't had cancer (except treated skin cancer) in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows up with adults who completed a previous mezagitamab trial for chronic immune thrombocytopenia (ITP). It monitors long-term safety and effectiveness of the treatment.
This trial tests a drug called belantamab mafodotin for adults with primary immune thrombocytopenia (ITP) whose platelet levels stayed low after trying steroids and another treatment like TPO-RA or rituximab. The goal is to see if it safely raises platelet counts.
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
This trial tests a drug called obinutuzumab for people with chronic ITP (low platelets) who haven't gotten better with steroids. The goal is to see if it can safely raise your platelet count.
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
This trial tests whether adding a new drug (telitacicept) to a standard platelet booster (eltrombopag) works better than eltrombopag alone for adults whose ITP has not responded to steroids.
Hear when a new Immune Thrombocytopenic Purpura (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.